Differences in platelet α-granule release between normals and immune thrombocytopenic patients and between young and old platelets

Henry M. Rinder, Jayne B. Tracey, Michael Recht, Laura DeCastro, Christine S. Rinder, Colleen McHugh, Brian R. Smith

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

The risk of serious bleeding in patients with immune thrombocytopenic purpura (ITP) appears to be less than in comparably thrombocytopenic patients with megakaryocytic hypoplasia. It has been proposed that this difference is due to enhanced hemostatic activity of young platelets, which are increased in the circulation during ITP. We examined α-granule release in reticulated platelets (RP), which are thought to be the youngest circulating platelets, and in older non-reticulated platelets (non-RP) in normal human controls and ITP patients. Normal controls had a mean RP of 7%, compared with 42% in ITP patients. The mean concentration of thrombin receptor agonist peptide (TRAP) causing 50% of control RP to express CD62P (EC50) was 0.82 ± 0.08 μM (SEM), significantly higher than the TRAP CD62P EC50 for RP in ITP, 0.57 ± 0.06 uM (p = 0.04). Similarly, the TRAP EC50 for non-RP in controls, 0.84 ± 0.09 μM, was significantly higher than in ITP, 0.56 ± 0.07 μM (p = 0.03), suggesting that all platelets in ITP have an enhanced α-granule threshold response to TRAP compared with controls, while RP and older platelets within each patient group have similar threshold sensitivities to TRAP. By contrast, high-dose TRAP caused RP to express twice as much mean and total CD62P as non-RP in both ITP patients and controls (p <0.05 for both comparisons). We conclude that compared with controls, all platelets in ITP are primed to undergo α-granule release to TRAP, while in both ITP and controls, the newly circulating, reticulated platelets have the potential to contribute greater amounts of CD62P surface ligand compared with older platelets (non-RP) after stimulation. Both the increased RP% and enhanced platelet response to agonist in ITP may contribute to maintenance of hemostasis despite thrombocytopenia.

Original languageEnglish (US)
Pages (from-to)457-462
Number of pages6
JournalThrombosis and Haemostasis
Volume80
Issue number3
StatePublished - Sep 1998
Externally publishedYes

Fingerprint

Blood Platelets
Idiopathic Thrombocytopenic Purpura
Thrombin Receptors
Peptides
Hemostatics
Hemostasis
Thrombocytopenia

ASJC Scopus subject areas

  • Hematology

Cite this

Rinder, H. M., Tracey, J. B., Recht, M., DeCastro, L., Rinder, C. S., McHugh, C., & Smith, B. R. (1998). Differences in platelet α-granule release between normals and immune thrombocytopenic patients and between young and old platelets. Thrombosis and Haemostasis, 80(3), 457-462.

Differences in platelet α-granule release between normals and immune thrombocytopenic patients and between young and old platelets. / Rinder, Henry M.; Tracey, Jayne B.; Recht, Michael; DeCastro, Laura; Rinder, Christine S.; McHugh, Colleen; Smith, Brian R.

In: Thrombosis and Haemostasis, Vol. 80, No. 3, 09.1998, p. 457-462.

Research output: Contribution to journalArticle

Rinder, Henry M. ; Tracey, Jayne B. ; Recht, Michael ; DeCastro, Laura ; Rinder, Christine S. ; McHugh, Colleen ; Smith, Brian R. / Differences in platelet α-granule release between normals and immune thrombocytopenic patients and between young and old platelets. In: Thrombosis and Haemostasis. 1998 ; Vol. 80, No. 3. pp. 457-462.
@article{bb4c8c82bd534fee8dcc3a31140139da,
title = "Differences in platelet α-granule release between normals and immune thrombocytopenic patients and between young and old platelets",
abstract = "The risk of serious bleeding in patients with immune thrombocytopenic purpura (ITP) appears to be less than in comparably thrombocytopenic patients with megakaryocytic hypoplasia. It has been proposed that this difference is due to enhanced hemostatic activity of young platelets, which are increased in the circulation during ITP. We examined α-granule release in reticulated platelets (RP), which are thought to be the youngest circulating platelets, and in older non-reticulated platelets (non-RP) in normal human controls and ITP patients. Normal controls had a mean RP of 7{\%}, compared with 42{\%} in ITP patients. The mean concentration of thrombin receptor agonist peptide (TRAP) causing 50{\%} of control RP to express CD62P (EC50) was 0.82 ± 0.08 μM (SEM), significantly higher than the TRAP CD62P EC50 for RP in ITP, 0.57 ± 0.06 uM (p = 0.04). Similarly, the TRAP EC50 for non-RP in controls, 0.84 ± 0.09 μM, was significantly higher than in ITP, 0.56 ± 0.07 μM (p = 0.03), suggesting that all platelets in ITP have an enhanced α-granule threshold response to TRAP compared with controls, while RP and older platelets within each patient group have similar threshold sensitivities to TRAP. By contrast, high-dose TRAP caused RP to express twice as much mean and total CD62P as non-RP in both ITP patients and controls (p <0.05 for both comparisons). We conclude that compared with controls, all platelets in ITP are primed to undergo α-granule release to TRAP, while in both ITP and controls, the newly circulating, reticulated platelets have the potential to contribute greater amounts of CD62P surface ligand compared with older platelets (non-RP) after stimulation. Both the increased RP{\%} and enhanced platelet response to agonist in ITP may contribute to maintenance of hemostasis despite thrombocytopenia.",
author = "Rinder, {Henry M.} and Tracey, {Jayne B.} and Michael Recht and Laura DeCastro and Rinder, {Christine S.} and Colleen McHugh and Smith, {Brian R.}",
year = "1998",
month = "9",
language = "English (US)",
volume = "80",
pages = "457--462",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "3",

}

TY - JOUR

T1 - Differences in platelet α-granule release between normals and immune thrombocytopenic patients and between young and old platelets

AU - Rinder, Henry M.

AU - Tracey, Jayne B.

AU - Recht, Michael

AU - DeCastro, Laura

AU - Rinder, Christine S.

AU - McHugh, Colleen

AU - Smith, Brian R.

PY - 1998/9

Y1 - 1998/9

N2 - The risk of serious bleeding in patients with immune thrombocytopenic purpura (ITP) appears to be less than in comparably thrombocytopenic patients with megakaryocytic hypoplasia. It has been proposed that this difference is due to enhanced hemostatic activity of young platelets, which are increased in the circulation during ITP. We examined α-granule release in reticulated platelets (RP), which are thought to be the youngest circulating platelets, and in older non-reticulated platelets (non-RP) in normal human controls and ITP patients. Normal controls had a mean RP of 7%, compared with 42% in ITP patients. The mean concentration of thrombin receptor agonist peptide (TRAP) causing 50% of control RP to express CD62P (EC50) was 0.82 ± 0.08 μM (SEM), significantly higher than the TRAP CD62P EC50 for RP in ITP, 0.57 ± 0.06 uM (p = 0.04). Similarly, the TRAP EC50 for non-RP in controls, 0.84 ± 0.09 μM, was significantly higher than in ITP, 0.56 ± 0.07 μM (p = 0.03), suggesting that all platelets in ITP have an enhanced α-granule threshold response to TRAP compared with controls, while RP and older platelets within each patient group have similar threshold sensitivities to TRAP. By contrast, high-dose TRAP caused RP to express twice as much mean and total CD62P as non-RP in both ITP patients and controls (p <0.05 for both comparisons). We conclude that compared with controls, all platelets in ITP are primed to undergo α-granule release to TRAP, while in both ITP and controls, the newly circulating, reticulated platelets have the potential to contribute greater amounts of CD62P surface ligand compared with older platelets (non-RP) after stimulation. Both the increased RP% and enhanced platelet response to agonist in ITP may contribute to maintenance of hemostasis despite thrombocytopenia.

AB - The risk of serious bleeding in patients with immune thrombocytopenic purpura (ITP) appears to be less than in comparably thrombocytopenic patients with megakaryocytic hypoplasia. It has been proposed that this difference is due to enhanced hemostatic activity of young platelets, which are increased in the circulation during ITP. We examined α-granule release in reticulated platelets (RP), which are thought to be the youngest circulating platelets, and in older non-reticulated platelets (non-RP) in normal human controls and ITP patients. Normal controls had a mean RP of 7%, compared with 42% in ITP patients. The mean concentration of thrombin receptor agonist peptide (TRAP) causing 50% of control RP to express CD62P (EC50) was 0.82 ± 0.08 μM (SEM), significantly higher than the TRAP CD62P EC50 for RP in ITP, 0.57 ± 0.06 uM (p = 0.04). Similarly, the TRAP EC50 for non-RP in controls, 0.84 ± 0.09 μM, was significantly higher than in ITP, 0.56 ± 0.07 μM (p = 0.03), suggesting that all platelets in ITP have an enhanced α-granule threshold response to TRAP compared with controls, while RP and older platelets within each patient group have similar threshold sensitivities to TRAP. By contrast, high-dose TRAP caused RP to express twice as much mean and total CD62P as non-RP in both ITP patients and controls (p <0.05 for both comparisons). We conclude that compared with controls, all platelets in ITP are primed to undergo α-granule release to TRAP, while in both ITP and controls, the newly circulating, reticulated platelets have the potential to contribute greater amounts of CD62P surface ligand compared with older platelets (non-RP) after stimulation. Both the increased RP% and enhanced platelet response to agonist in ITP may contribute to maintenance of hemostasis despite thrombocytopenia.

UR - http://www.scopus.com/inward/record.url?scp=0031757218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031757218&partnerID=8YFLogxK

M3 - Article

C2 - 9759627

AN - SCOPUS:0031757218

VL - 80

SP - 457

EP - 462

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 3

ER -